Evidence map›Paper›PMID 28939212›Full record

ReviewAdvances in clinical chemistry

Fortilin: A Potential Target for the Prevention and Treatment of Human Diseases.

Decha Pinkaew, Ken Fujise

Abstract readReview
In one paragraph

Review in Advances in clinical chemistry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
7.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. High Plasma Levels of Fortilin in Patients with Coronary Artery Disease.International journal of molecular sciences · 2022
    Article
  7. Article
  8. Article
  9. Review
  10. Repurposing Drugs to Treat Heart and Brain Illness.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Decha PinkaewUniversity of Texas Medical Branch at Galveston, Galveston, TX, United States.
Ken FujiseUniversity of Texas Medical Branch at Galveston, Galveston, TX, United States; The Institute of Translational Sciences, University of Texas Medical Branch at Galveston, Galveston, TX, United States. Electronic address: ken.fujise@utmb.edu.
The University of Texas Medical Branch at Galveston · US

Funding

Fortilin, p53, and atherosclerosisR01HL117247 · NHLBI · UNIVERSITY OF WASHINGTON · PI CHEN, SHIYOU, FUJISE, KEN · 2013 to 2023
$4.7M
Novel mechanism of smooth muscle phenotypic modulation and vascular remodelingR01HL119053 · NHLBI · UNIVERSITY OF MISSOURI-COLUMBIA · PI CHEN, SHIYOU · 2014 to 2023
$3.8M
USING FORTILIN INHIBITORS TO BLOCK ATHEROSCLEROSISR01HL138992 · NHLBI · UNIVERSITY OF WASHINGTON · PI FUJISE, KEN, SRIVASTAVA, SANJAY · 2017 to 2020
$2.6M
NHLBI NIH HHS R01 HL117247NHLBI NIH HHS R01 HL119053NHLBI NIH HHS R01 HL138992
6 · The paper itself

Abstract

Fortilin is a highly conserved 172-amino-acid polypeptide found in the cytosol, nucleus, mitochondria, extracellular space, and circulating blood. It is a multifunctional protein that protects cells against apoptosis, promotes cell growth and cell cycle progression, binds calcium (Ca

Indexed as

NeoplasmsAnimalsAtherosclerosisBacterial InfectionsBiomarkersBiomarkers, TumorDiabetes MellitusHumansHypertension, PulmonaryLiver DiseasesMalariaTumor Protein, Translationally-Controlled 1Virus DiseasesBiomarkersBiomarkers, TumorTPT1 protein, humanTumor Protein, Translationally-Controlled 1Alcohol liver injuryApoptosisAtherosclerosisCancersDevelopmentDiabetes mellitusEndoplasmic reticulum (ER) stressFortilinHistamine-releasing factorHost defenseHRFHypertensionImmunityIRE1αLiver regenerationPulmonary arterial hypertensionTCTPTPT1Translationally controlled tumor proteinTumors

Identifiers

PMID28939212
PMCPMC6064975
OpenAlexW2744336818

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.